Results 1 to 10 of about 1,730 (116)

Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG

BMC Health Services Research, 2020
Background The question of how to set the cost-effectiveness threshold for new, innovative medicines is a matter of ongoing controversy. One prominent proposal suggests that the cost-effectiveness threshold adopted by the U.K.
Afschin Gandjour
exaly   +3 more sources

Identifying Minimum Threshold Level of Trial Crossover Rates Yielding Nonsignificant Overall Survival Benefit Associated with Cancer Treatments: A Systematic Literature Review of HTA Submissions [PDF]

Journal of Health Economics and Outcomes Research
# Background Crossover distortion in oncology trials occurs when control-arm patients switch to agent(s) in the experimental arm, potentially attenuating treatment effects in intention-to-treat (ITT) overall survival (OS) analyses.
Anandaroop Dasgupta, Ankita Kaushik, Barinder Singh, Sumeet Attri, Billy Amzal, Oleg Gluz   +5 more
doaj   +2 more sources

Acceptability of external control-arm use in nononcology health technology assessment submissions [PDF]

Journal of Comparative Effectiveness Research
Aim: This study assessed the acceptability of external control-arm (ECA) use in nononcology health technology assessment (HTA) submissions in Europe. Materials & methods: We conducted a sequential mixed method study to investigate the study objective ...
Kamal Kant Mangla, Spyros Kolovos, Ana Lisica, Max Schlueter, Nick Fabrin Nielsen   +4 more
doaj   +2 more sources

Correction: Performance of several types of beta-binomial models in comparison to standard approaches for meta-analyses with very few studies [PDF]

BMC Medical Research Methodology
Moritz Felsch, Lars Beckmann, Ralf Bender, Oliver Kuss, Guido Skipka, Tim Mathes   +5 more
doaj   +2 more sources

Single-fraction stereotactic radiosurgery versus microsurgical resection for the treatment of vestibular schwannoma: a systematic review and meta-analysis

Systematic Reviews, 2022
Background Vestibular schwannomas are benign tumours for which various treatments are available. We performed a systematic review of prospective controlled trials comparing the patient-relevant benefits and harms of single-fraction stereotactic ...
Thomas Jakubeit, Sibylle Sturtz, Dorothea Sow, Wolfram Groß, Christoph Mosch, Mattea Patt, Vera Weingärtner, Jan Boström, Roland Goldbrunner, Martina Markes   +9 more
doaj   +1 more source

Negative pressure wound therapy in patients with wounds healing by secondary intention: a systematic review and meta-analysis of randomised controlled trials

Systematic Reviews, 2020
Background Negative pressure wound therapy (NPWT) is a widely used method of wound treatment. We performed a systematic review of randomised controlled trials (RCTs) comparing the patient-relevant benefits and harms of NPWT with standard wound therapy ...
Yvonne Zens, Michael Barth, Heiner C. Bucher, Katrin Dreck, Moritz Felsch, Wolfram Groß, Thomas Jaschinski, Heike Kölsch, Mandy Kromp, Inga Overesch, Stefan Sauerland, Sven Gregor   +11 more
doaj   +1 more source

A simulation study to compare different estimation approaches for network meta-analysis and corresponding methods to evaluate the consistency assumption

BMC Medical Research Methodology, 2020
Background Network meta-analysis (NMA) is becoming increasingly popular in systematic reviews and health technology assessments. However, there is still ambiguity concerning the properties of the estimation approaches as well as for the methods to ...
Corinna Kiefer, Sibylle Sturtz, Ralf Bender   +2 more
doaj   +1 more source

Performance of several types of beta-binomial models in comparison to standard approaches for meta-analyses with very few studies

BMC Medical Research Methodology, 2022
Background Meta-analyses are used to summarise the results of several studies on a specific research question. Standard methods for meta-analyses, namely inverse variance random effects models, have unfavourable properties if only very few (2 – 4 ...
Moritz Felsch, Lars Beckmann, Ralf Bender, Oliver Kuss, Guido Skipka, Tim Mathes   +5 more
doaj   +1 more source

Auswirkungen der neuen Dossieranforderungen

Monitor Versorgungsforschung, 2023
Bei Markteintritt oder Zulassungserweiterung eines neuen Arzneimittels sind pharmazeutische Unternehmer in Deutschland seit 2011 zur Einreichung eines AMNOG-Nutzendossiers beim G-BA verpflichtet.
Dr. rer. nat. Maria Katharina Schweitzer, Dr. rer. nat. Manuel Nico Dold, Dr. rer. nat. Astrid Genet, Klaus Gossens PhD, Dipl.-Math. Thomas Klein-Hessling, Nils Löffler MSc, Dr. phil. Matthias Rabel, Dr. PH Andrej Rasch, Jessica Schmelcher MSc, Dr. rer. nat. Sebastian Werner, Natalia Wolfram   +10 more
doaj   +1 more source

Real-world clinical practice in health technology assessment: state of the art for 2022

Реальная клиническая практика: данные и доказательства, 2023
The real-world data are used in drug authorization procedures, comparative efficacy and safety research, to make changes in the Summary of Product Characteristics, clinical recommendations.
A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin   +2 more
doaj   +1 more source